MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma
Abstract Glioblastoma (GBM) is an aggressive nervous system tumor with a poor prognosis. Although, surgery, radiation therapy, and chemotherapy are the current standard protocol for GBM patients, there is still a poor prognosis in these patients. Temozolomide (TMZ) as a first-line therapeutic agent...
| 出版年: | Molecular Brain |
|---|---|
| 主要な著者: | , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
BMC
2024-07-01
|
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s13041-024-01113-6 |